Evonik's €21.42 Close: A Pharma Innovation Story Drowning in Takeover Noise

Evonik closed at €21.42, just below its 52-week high, as BASF takeover speculation and RAG-Stiftung's silence drive the stock's roughly 60% YTD gain.

Evonik's stock ended Friday's session at €21.42, just shy of the 52-week high of €21.62 touched earlier the same day — a peak that caps a year-to-date advance of roughly 60%. Yet the Essen-based specialty chemicals group's share price is being driven less by its own operational achievements than by speculation swirling around a potential takeover by Ludwigshafen rival BASF.

A Foundation That Won't Tip Its Hand

The single most consequential gatekeeper in any deal scenario is the RAG-Stiftung, Evonik's largest shareholder. Its board of trustees convened online on Friday to receive a briefing on BASF's reported interest, according to Handelsblatt. No decision on how to proceed emerged from that meeting. Without the foundation's blessing, any approach is widely regarded as dead on arrival.

That silence sits at the heart of the current impasse. BASF has not tabled a formal offer, and Evonik reiterated on Friday that no talks are underway between the two chemical giants. Reuters, citing two sources close to BASF, reported that the Ludwigshafen group is weighing a higher bid should formal discussions ever materialise — a scenario that remains purely hypothetical for now.

Political Headwinds From Düsseldorf

North Rhine-Westphalia's state government added its voice to the chorus of caution on 5 October. Per Reuters, officials in Düsseldorf made clear that jobs at Evonik and the company's independent development must not be jeopardised by any takeover. The fear of losing industrial employment in the region underpins that stance.

Organised labour has also mobilised. The IGBCE union urged works councils at both companies on Thursday to scrutinise the plans in detail, signalling that any deal would face intense scrutiny from employee representatives.

Berenberg Shifts Gears

Against this uncertain backdrop, Berenberg adjusted its view on 5 October, upgrading Evonik from "Sell" to "Hold" and lifting its price target to €20 from €15.50. Analyst Sebastian Bray pointed squarely at BASF's takeover interest as the rationale — a tacit acknowledgment that M&A speculation, rather than fundamentals, is now the primary force moving the stock.

That dynamic places Evonik's management in an awkward position. The company continues to execute its own strategy while the market values its shares largely through the lens of a possible transaction, creating a disconnect between operational reality and market-driven expectation.

Innovation Momentum Continues Regardless

The takeover chatter has hardly frozen Evonik's research engine. On 5 October the group unveiled a new biodegradable polymer platform designed to serve as the foundation for future generations of EUDRAGIT-branded excipients used in targeted oral drug delivery. Initial non-commercial laboratory quantities are already available for joint development projects with selected partners.

Days later, at the CPHI trade fair in Milan on 6 October, Evonik collected the CPHI Pharma Award 2026 in the "Digital Transformation" category for its Self Driving Labs initiative — a further signal that the company is deepening its push into research-intensive, higher-margin specialty applications.

Two Forces, One Share Price

For investors, the picture is bifurcated. On one side stands a company demonstrating genuine technological substance in profitable pharmaceutical niches. On the other, its valuation hinges on decisions being weighed in Ludwigshafen and the posture of the RAG-Stiftung — a dual-track reality that has delivered strong gains but left the stock's next move contingent on forces well beyond Evonik's own laboratories.